Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.58 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546117 | 0.90 | CYP3A4 (0.64) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL2536418 | 0.89 | CYP2C19 (0.68) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL2538810 | 0.88 | CYP3A4 (0.74) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL2541123 | 0.88 | CYP3A4 (0.63) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL2546160 | 0.88 | CYP2C19 (0.58) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL12258419 | 0.81 | CYP3A4 (0.51) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL1891866 | 0.78 | CYP3A4 (0.79) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL1893036 | 0.78 | CYP2C19 (0.64) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL31290941 | 0.78 | CYP2C19 (0.64) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL1888518 | 0.78 | CYP2C19 (0.61) | CYP3A4CYP2C19CYP2C9KITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2560972-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2560972-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-8901118-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901118-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2560972-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133637-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133637-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | CYP3A4 3791/4885CYP2C19 3444/4885CYP2C9 3483/4885 |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | CYP3A4 3835/4885CYP2C19 3417/4885CYP2C9 3333/4885 |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | CYP3A4 3841/4885CYP2C19 3527/4885CYP2C9 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.